OUR VISION

WE ASPIRE TO CONQUER CANCER

By addressing the unmet medical needs of our
patients with paradigm-shifting therapeutics

Our Pipeline

  • PROGRAM
  • DISCOVERY
  • PRECLINICAL
  • PHASE 1
  • PHASE 2

VersAptx™ Platform

VIP236

αvβ3 - optCPT SMDC
First-in-Class
  • DISCOVERY
  • PRECLINICAL
  • PHASE 1
  • PHASE 2
Multiple Solid Tumors

VIP943

Anti-CD123 - KSPi ADC
Best-in-Class
  • DISCOVERY
  • PRECLINICAL
  • PHASE 1
  • PHASE 2
Leukemias & Myelodysplastic Syndrome (MDS)

VIP924

Anti-CXCR5 - KSPi ADC
First-in-Class
  • DISCOVERY
  • PRECLINICAL
  • PHASE 1
  • PHASE 2
B-cell Malignancies

Anti-CD33 - KSPi ADC
  • DISCOVERY
  • PRECLINICAL
  • PHASE 1
  • PHASE 2
Leukemias & MDS

Undisclosed Target 1 - KSPi ADC
  • DISCOVERY
  • PRECLINICAL
  • PHASE 1
  • PHASE 2
Solid Tumors

Undisclosed Target 2 - KSPi ADC
  • DISCOVERY
  • PRECLINICAL
  • PHASE 1
  • PHASE 2
Solid Tumors

P-TEFb Program

ENITOCICLIB

ENITOCICLIB* CDK9 inhibitor
Best-in-Class
  • DISCOVERY
  • PRECLINICAL
  • PHASE 1
  • PHASE 2
MYC-rearranged , Diffuse Large B-cell Lymphoma (DLBCL), Non-GCB DLBCL, Peripheral T-cell Lymphoma (in partnership with NIH)

*Also known as VIP152.
ADC, antibody-drug conjugate; CDK, cyclin-dependent kinase;  GCB, germinal center B-cell;  intravenous; KSPi, kinesin spindle protein inhibitor;  optCPT, optimized camptothecin; P-TEFb, positive transcription elongation factor B; SMDC, small molecule drug conjugate.

VINCERX PHARMA 
NEWS

Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

 

Read More